Equities Analysts Issue Forecasts for CNTX FY2025 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Investment analysts at Lifesci Capital issued their FY2025 earnings estimates for Context Therapeutics in a research report issued to clients and investors on Monday, February 23rd. Lifesci Capital analyst C. Zhu expects that the company will post earnings per share of ($0.36) for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.55) EPS.

CNTX has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. JonesTrading started coverage on Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 price objective on the stock. Wall Street Zen raised Context Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 16th. D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research note on Thursday, November 6th. Finally, HC Wainwright raised their target price on shares of Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Context Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Context Therapeutics Price Performance

Shares of Context Therapeutics stock opened at $2.43 on Wednesday. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.85. The company’s fifty day simple moving average is $1.86 and its 200-day simple moving average is $1.33. The stock has a market capitalization of $223.27 million, a PE ratio of -10.13 and a beta of 1.94.

Institutional Trading of Context Therapeutics

Several hedge funds have recently bought and sold shares of CNTX. Millennium Management LLC bought a new stake in shares of Context Therapeutics in the fourth quarter worth about $3,824,000. Marshall Wace LLP grew its holdings in Context Therapeutics by 7,153.7% during the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after buying an additional 2,557,448 shares in the last quarter. State Street Corp grew its holdings in Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after buying an additional 13,000 shares in the last quarter. Renaissance Technologies LLC increased its stake in Context Therapeutics by 58.8% in the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after acquiring an additional 188,202 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after acquiring an additional 134,449 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Key Headlines Impacting Context Therapeutics

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Lifesci Capital upgraded CNTX to a “Strong-Buy” and published detailed quarterly and full-year EPS forecasts (showing expected losses through FY2026), signaling institutional conviction and raising visibility among growth/biotech investors. MarketBeat: Lifesci Capital Research on CNTX
• Neutral Sentiment: Short-interest data for February appears inconsistent (reporting 0 shares and NaN change vs. prior period), which is likely a reporting/data error — this creates ambiguity about whether bearish short activity is increasing or not and can contribute to volatile intraday moves. (No external link provided)
• Neutral Sentiment: Background technicals: CNTX remains volatile with a 12‑month trading range well below its recent high and lighter-than-average volume today, meaning headlines and analyst notes can have outsized impact until volume normalizes. Zacks: Context Therapeutics Coverage

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.